Article

Medisarang Opens R&D Center to Advance Autologous Blood-Based Regenerative Medicine Technologies

작성일 : 2026.09.11
조회수 : 21

https://www.edaily.co.kr/News/Read?newsId=03899926645579136&mediaCodeN… [3]

Expanding Joint Research with Medical Institutions and Leveraging Research Data for Product Advancement

[Edaily, Reporter Lee Jung-hoon] Medisarang, a medical device company specializing in autologous blood-based regenerative medicine, announced on the 11th that it has opened a new Research and Development (R&D) Center as part of its efforts to establish a more systematic R&D framework.

he newly opened R&D Center will focus on regenerative medicine technologies derived from autologous blood and bone marrow, including Platelet-Rich Plasma (PRP), Platelet-Rich Fibrin (PRF), and Bone Marrow Aspirate Concentrate (BMAC). Based on product performance evaluations and analytical data, the center will assess and enhance the technical maturity of existing products while applying accumulated research findings to the development of new products.

Medisarang also plans to expand joint research initiatives with medical institutions. By incorporating physicians’ clinical experience and research data into the development process, the company aims to develop products and application protocols that are better suited to real-world clinical settings. Evidence generated through these collaborative research efforts will be used to strengthen the reliability of its technologies and serve as a foundation for evaluating their potential future clinical applications.

“The opening of our R&D Center marks an important turning point in advancing the product development and manufacturing technologies we have accumulated over the years through stronger scientific data and research capabilities,” said Soo-ja Shim, CEO of Medisarang. “We will continue to strengthen our in-house R&D capabilities while expanding collaboration with medical institutions and research organizations.”

“We will translate the data generated through our research into greater product competitiveness and strengthen our position in both domestic and global markets by promoting the standardization and reliability of autologous blood-based regenerative medicine technologies,” she added.

Centered around the new R&D Center, Medisarang will operate an integrated research and development framework encompassing technology development, performance evaluation, data accumulation, clinical collaboration, and product advancement. The company plans to further improve the technical maturity of its existing products while continuously developing new products and technologies that reflect both clinical needs and research findings.

Medisarang specializes in the research and development of medical devices and related technologies in the field of autologous blood- and bone marrow-derived regenerative medicine, including PRP, PRF, and BMAC. By integrating product development, manufacturing, performance evaluation, and collaboration with medical institutions, the company is committed to strengthening its technology competitiveness based on scientific evidence and advancing products that address the practical needs of clinical settings.